https://www.selleckchem.com/products/su6656.html
Although erenumab has demonstrated significant reduction in migraine frequency and improved quality of life in studies lasting 3 to 12months, little is known about long-term therapy. This study was an open-label, 5-year treatment phase following a 12-week, double-blind, placebo-controlled trial in adults with episodic migraine. Patients initially received open-label erenumab 70mg, which increased to 140mg following a protocol amendment. Efficacy analyses included change from baseline in monthly migraine days (MMDs), monthly acute migrain
Like
Comment
Share
